Full-Time

Omnichannel Lead

Solid Tumor

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$154.4k - $242.6k/yr

+ Short-term incentives + Long-term incentives + 401(k) company match

Boston, MA, USA

Hybrid

Approximately 10% travel is required, including possible overnight travel.

Bachelor's

Category
Growth & Marketing
Required Skills
Market Research
CRM
Social Media
SEO
A/B Testing
Financial analysis
Data Analysis

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A Bachelor's degree.
  • At least 8 years of experience with increasing responsibilities in a digital agency, marketing, or related function, preferably with pharmaceutical or healthcare industry experience.
  • Deep understanding of multichannel marketing tactics and digital channels, including email, websites, webinars/webcasts, digital media programs, paid search, search engine optimization, social media, mobile applications, digital sales aids, and measurement and insight generation.
  • Demonstrated experience leveraging customer journeys and experience maps to engage target audiences during moments that matter and creating personalized, omnichannel solutions with the individual in mind.
  • Experience managing and driving accountability with multiple agencies of record to develop and execute marketing tactics on time and within budget.
  • Experience with A/B testing across channels and content types.
  • Strong analytical skills with the demonstrated ability to assess business results of marketing tactics, define appropriate key performance indicators, and maximize the value of marketing investment.
  • Proven experience advising stakeholders and effectively influencing business partners and peers.
  • Demonstrated ability to thoroughly learn new markets, disease states, and products quickly.
  • Strong consultative skills, including discovery, detailed business analysis, workshop facilitation, roadmap planning, project management, and interpersonal communication.
  • Ability to influence and persuade stakeholders in a wide range of departments and at varying levels of seniority, including senior leadership in the United States and globally.
  • A self-motivated ability to work collaboratively and cross-functionally with Brand Marketing, Insights and Analytics, DD&T, Sales, Patient Services, and other key partners.
  • Financial management and budgeting abilities.
Responsibilities
  • Lead the development and implementation of the omnichannel plan for Solid Tumor customers, including healthcare professionals and patients.
  • Design and implement seamless, brand-specific customer experiences and omnichannel plans using data, insights, external trends, and benchmarks.
  • Design and deploy healthcare professional omnichannel experience plans for different personas and adoption levels, including customer journeys, messaging, delivery, and channel optimization.
  • Create strategic campaigns in non-personal channels that integrate with personal promotion efforts to improve customer engagement and adoption, including representative-triggered emails and alert activation.
  • Collaborate with Solid Tumor Marketing, Sales, Insights and Analytics, Medical, PVA, RC, and agency partners to design, build, and deploy omnichannel campaigns for healthcare professionals and patients.
  • Drive meaningful and measurable engagement with audience segments and use promotional mix analyses to make resource-allocation decisions that optimize campaign resonance and impact.
  • Lead healthcare professional and patient media strategy with agencies and partners and track performance to adapt plans in an agile manner.
  • Analyze customer behavior using customer relationship management data and analytics to track engagement and optimize the customer experience.
  • Lead the healthcare professional and patient experience measurement plan and adapt it accordingly.
  • Define the vision, strategy, and implementation of healthcare professional and patient omnichannel solutions that improve customer experience and support brand goals.
  • Partner with brand teams and cross-functional partners to identify healthcare professional and patient targets and design personalized campaigns across web, search engine optimization and search engine marketing, email, direct mail, social media, and digital advertising.
  • Create agile content and implement brand-strategy initiatives involving website design, personalization and optimization, search engine optimization, paid search, customer relationship management, digital display media, and social media.
  • Identify trends and insights with agencies and Insights and Analytics to understand customer engagement and campaign performance and optimize customer plans, spending, and return on investment.
  • Implement identified technologies.
  • Use audience research and trend analysis to develop modular, personalized content and evaluate customer research, market conditions, and competitor activities.
  • Establish objectives and performance metrics for omnichannel campaigns with Insights and Analytics and agency partners and recommend campaign optimizations to improve performance.
  • Work cross-functionally to understand customer and business needs and align recommendations and strategy with different audience segments.
  • Improve the financial performance of campaigns through business analysis, financial analysis, continuous process improvements, and project budget management.
  • Manage agency partner relationships, expectations, budgets, and contract reviews.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval for MIMRYLO unlocks near-term U.S. oncology revenue.
  • Takeda expects ORZEYFUL U.S. launch by November 2026, pending DEA scheduling.
  • Q1 FY2026 new launches grew 22.6%, offsetting mature-brand declines and supporting guidance.

What critics are saying

  • May 18, 2026 AMITIZA verdict exposed Takeda to $2.6 billion treble-damage risk.
  • Takeda plans 4,500 FY2026 cuts, signaling launch execution pressure and organizational churn.
  • Patent erosion crushed VYVANSE sales 60.7% at constant currency in Q1 FY2026.

What makes Takeda unique

  • ORZEYFUL became the first orexin agonist approved for narcolepsy type 1 in 2026.
  • MIMRYLO offers first-in-class hepcidin mimetic therapy for polycythemia vera after FDA approval.
  • Takeda pairs global scale with Japanese discovery, including Shonan-led neurology innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Sep 9th, 2026
Trialbee unveils AI-powered patient screening chatbot at DPHARM 2026

Trialbee, a patient recruitment platform provider, will present at DPHARM 2026 in Boston on 15-16 September. The Swedish-American company will unveil AI-powered patient screening in its Honey Platform, enabling conversational AI chatbots to conduct initial candidate assessments whilst giving patients the option to speak with recruitment specialists. Trialbee will present jointly with pharmaceutical company Takeda on integrating their respective platforms to build research-ready patient communities that extend beyond single trials. The company will also participate in a panel discussing AI applications at clinical trial sites. The Honey Platform has added several AI features this year, including candidate summaries, duplicate detection, and recruitment data analysis. Trialbee supports over 6,000 research sites across 50 countries and reports a 91% repeat business rate with biopharmaceutical companies.

Associated Press
Sep 9th, 2026
Onco360 selected as specialty pharmacy partner for rare blood cancer drug MIMRYLO

Onco360, a US independent speciality pharmacy, has been selected by Takeda Pharmaceuticals as an ultra-narrow limited distribution partner for MIMRYLO (rusfertide). The treatment is indicated for erythrocytosis in adults with polycythemia vera. MIMRYLO is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin. This inhibition reduces iron availability for red blood cell production, resulting in lower hematocrit levels. The drug's approval was based on the phase 3 VERIFY study, a global, randomised, open-label clinical trial. The primary endpoint measured the proportion of patients achieving response during weeks 20-32, defined as the absence of phlebotomy eligibility. The most common adverse reactions were injection site reactions at 56% and anaemia at 16%.

Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.